Reata Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Reata Pharmaceuticals

28/02/2022 14:32

* Reata Pharmaceuticals Inc  RETA.OQ  reported a quarterly
adjusted loss of $2.35​​ per share for the quarter ended in
December. The mean expectation of nine analysts for the quarter
was for a loss of $2.31 per share.
    * Revenue fell 70.7% to $934.00 thousand from a year ago; 
analysts expected $1.63 million. 
    * Reata Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.35​.
    * The mean earnings estimate of analysts had risen by
about 3.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Reata Pharmaceuticals Inc shares had fallen by 0.9% this
quarter.
    * The company reported a quarterly loss of $85.39 million.
    * Wall Street's median 12-month price target for Reata
Pharmaceuticals Inc is $43.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 28 at 02:32 p.m.
 ​All figures in US dollars unless otherwise stated